Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flow from operating activities:
Net loss	$ (8,106,695)	$ (1,828,080)
Adjustments to reconcile net loss to net cash used in operating activities:
Recognition of credit loss on notes receivable		795,353
Accrued interest revenue		(42,746)
Loss on equity method investment		439,637
Gain on revaluation of equity method investment		(6,164,260)
Gain on note receivable in connection with asset purchase	(1,290,000)
Depreciation and amortization	402,738	259,362
Vesting expense	422,777	1,644,220
Equity instruments issued for management, consultant, and other	(397,300)
Amortization of debt discount	858,353	1,068,256
Loss on valuation of equity-linked instruments and derivative liability	394,974	231,348
Gain on revaluation of cash advances to Helomics		(1,222,244)
Debt extinguishment costs	300,000
Equity instruments issued in connection with 2020 convertible debt	20,695
Loss on fixed asset disposal	118,472
Changes in assets and liabilities:
Accounts receivable	113,769	141,325
Inventories	(45,212)	(55,665)
Prepaid expense and other assets	(197,182)	66,989
Accounts payable	(614,651)	718,483
Accrued expenses	505,380	(104,114)
Deferred revenue	(1,802)	6,641
Net cash used in operating activities	(6,721,084)	(4,045,495)
Cash flow from investing activities:
Advance on notes receivable		(975,000)
Cash received from notes receivable		154,418
Cash received in Helomics Acquisition		248,102
Proceeds from asset sales	133,850
Acquisition of intangibles	(43,874)	(8,433)
Net cash provided by (used in) investing activities:	89,976	(580,913)
Cash flow from financing activities:
Extinguishment of convertible debt		(220,241)
Proceeds from debt issuance	2,761,867	1,525,000
Proceeds from exercise of warrants into common stock	1,866,554	5,786
Proceeds from issuance of Series E convertible preferred stock		743,560
Repayment of debt	(1,459,973)
Payment penalties	(247,327)
Proceeds from issuance of common stock pursuant to equity line	1,869,899
Issuance of common stock, A, B and prefunded warrants, net	5,057,919	2,479,708
Other financing (security deposit)	25,416
Net cash provided by financing activities	9,874,355	4,533,813
Net increase (decrease) in cash and cash equivalents	3,243,247	(92,595)
Cash at beginning of period	150,831	162,152
Cash at end of period	3,394,078	69,557
Non-cash transactions:
Bridge loan conversion into common stock	$ 267,328	$ 238,573
Shares issued pursuant to CEO note conversion and accrued interest and exchange agreement (in shares)	2,322,878
Inducement shares issued pursuant to convertible debt	$ 99,305
Inducement shares issued for debt extension	41,250
Warrants issued pursuant to debt issuance	179,324
Put and conversion derivative from debt issuance	141,463
Series D preferred stock conversions	35,000
Increase to operating lease right of use asset and lease liability due to lease modification	995,571
Asset purchase acquired for notes receivable and common stock	1,492,500
Forbearance settlement bridge loan		503,009
Additional warrants issued pursuant to CEO note payable		32,215
Consideration given for acquisition of Helomics		26,711,191
Series E Convertible Preferred Stock [Member]
Non-cash transactions:
Series E preferred stock conversions	$ 3